{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:31:04Z","timestamp":1789133464111,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2018-35-2003"],"award-info":[{"award-number":["Z-2018-35-2003"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["252300421612"],"award-info":[{"award-number":["252300421612"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070120"],"award-info":[{"award-number":["82070120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.blre.2025.101356","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:54:13Z","timestamp":1764834853000},"page":"101356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies"],"prefix":"10.1016","volume":"75","author":[{"given":"Xuewen","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101356_bb0005","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101356_bb0010","first-page":"1","volume":"7","author":"Berntorp","year":"2021","journal-title":"Haemophilia Nat Rev Dis Primers"},{"key":"10.1016\/j.blre.2025.101356_bb0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of Hemophilia in males","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2025.101356_bb0020","series-title":"GeneReviews\u00ae","article-title":"Hemophilia B","author":"Konkle","year":"1993"},{"key":"10.1016\/j.blre.2025.101356_bb0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3727\/096368910X503398","article-title":"Genetic modification of donor hepatocytes improves therapeutic efficacy for Hemophilia B in mice","volume":"19","author":"Wu","year":"2010","journal-title":"Cell Transplant"},{"key":"10.1016\/j.blre.2025.101356_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13287-025-04195-8","article-title":"Development of iPSC-derived FIX-secreting hepatocyte sheet as a novel treatment tool for hemophilia B treatment","volume":"16","author":"Bayarsaikhan","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for Hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.blre.2025.101356_bb0040","series-title":"Madame Curie Bioscience Database [Internet], Landes Bioscience","article-title":"Hepatocyte transplantation and liver-directed gene therapy","author":"Guha","year":"2013"},{"key":"10.1016\/j.blre.2025.101356_bb0045","article-title":"The critical need to consolidate all gene therapy data in haemophilia","volume":"n\/a","author":"Konkle","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101356_bb0050","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/gt.2008.71","article-title":"AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects","volume":"15","author":"Hasbrouck","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101356_bb0060","series-title":"Long-Term Evaluation of Liver Health in Participants Who Received Fidanacogene Elaparvovec: Data From a Phase 1\/2a Study With Up to 6 Years of Follow-up","first-page":"508","author":"Ducore","year":"2024"},{"key":"10.1016\/j.blre.2025.101356_bb0065","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101356_bb0070","series-title":"A Study to Evaluate the Safety, Tolerability and Efficacy of an Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor IX Transgene (BBM-H901) Injection in Patients with Hemophilia B. clinicaltrials.gov","author":"Shanghai Belief-Delivery BioMed Co., Ltd","year":"2025"},{"key":"10.1016\/j.blre.2025.101356_bb0075","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101356_bb0080","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/v16071125","article-title":"Viral vector based immunotherapy for peanut allergy","volume":"16","author":"Gonzalez-Visiedo","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.blre.2025.101356_bb0085","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jhep.2023.10.029","article-title":"Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists","volume":"80","author":"M\u00fccke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.blre.2025.101356_bb0090","first-page":"1","article-title":"Incomplete elimination of viral genomes is associated with chronic inflammation in nonhuman primate livers after AAV-mediated gene transfer","author":"Pichard","year":"2025","journal-title":"Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/hum.2024.179","article-title":"Current and emerging issues in adeno-associated virus vector-mediated liver-directed gene therapy","volume":"36","author":"Piccolo","year":"2025","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0100","first-page":"11","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101356_bb0105","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0110","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3389\/fimmu.2018.02379","article-title":"Pattern recognition receptors and the host cell death molecular machinery","volume":"9","author":"Amarante-Mendes","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101356_bb0115","first-page":"131","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","author":"Muhuri","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101356_bb0120","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101356_bb0125","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.blre.2025.101356_bb0135","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11901-023-00624-5","article-title":"Hepatotoxicity in adeno-associated viral vector gene therapy","volume":"22","author":"Jagadisan","year":"2023","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.blre.2025.101356_bb0140","doi-asserted-by":"crossref","first-page":"10721","DOI":"10.3748\/wjg.v21.i38.10721","article-title":"Restoring homeostasis of CD4+ T cells in hepatitis-B-virus-related liver fibrosis","volume":"21","author":"Cheng","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.blre.2025.101356_bb0145","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/cmi.2010.5","article-title":"Th17 cells and their associated cytokines in liver diseases","volume":"7","author":"Lafdil","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.blre.2025.101356_bb0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12964-024-01505-0","article-title":"The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient \u201cyin-Yang\u201d theory and modern immunology","volume":"22","author":"Cui","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.blre.2025.101356_bb0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/hum.2014.109","article-title":"Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial","volume":"26","author":"Ferla","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41434-024-00441-5","article-title":"Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia","volume":"31","author":"Pabinger","year":"2024","journal-title":"Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0165","series-title":"Natural history of AAV5 neutralising antibodies in adults withhaemophilia B during \u22656-month screening and lead-in to theHOPE-B trial with etranacogene dezaparvovec gene therapy","author":"Klamroth","year":"2025"},{"key":"10.1016\/j.blre.2025.101356_bb0170","first-page":"13","article-title":"A versatile toolkit for overcoming AAV immunity","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101356_bb0175","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood-2019-128217","article-title":"Seroprevalence of pre-existing nabs against AAV1, 2, 5, 6 and 8 in south African Hemophilia B patient population","volume":"134","author":"Majowicz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101356_bb0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/hum.2023.225","article-title":"Prevalence study of cellular capsid-specific immune responses to AAV2, 4, 5, 8, 9, and rh10 in healthy donors","volume":"35","author":"Xicluna","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0185","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1525-0016(16)40508-3","article-title":"66. Gene therapy for Hemophilia B by novel serotypes of AAV vectors","volume":"7","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.blre.2025.101356_bb0195","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec gene therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101356_bb0200","series-title":"Gene Therapy for Chinese Hemophilia B With Adeno-associated Virus (AAV) Vector clinicaltrialsgov","author":"Institute of Hematology & Blood Diseases Hospital, China","year":"2025"},{"key":"10.1016\/j.blre.2025.101356_bb0205","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with Fidanacogene Elaparvovec in adults with Hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101356_bb0210","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101356_bb0215","series-title":"Open-label, Single-arm Study to Evaluate Efficacy and Safety of FIX Gene Transfer With PF-06838435 (rAAV-Spark100-hFIX-R338L) in Adult Male Participants With Moderately Severe to Severe Hemophilia B (FIX:C \u22642%) (BeneGene-2). clinicaltrials.gov","author":"Pfizer","year":"2025"},{"key":"10.1016\/j.blre.2025.101356_bb0220","author":"Behring","year":"2025"},{"key":"10.1016\/j.blre.2025.101356_bb0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.14907","article-title":"Gene therapy for haemophilia a and B, from basic principles to clinical implementation: an illustrated review","volume":"30","author":"Ay","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101356_bb0230","first-page":"32","article-title":"B cell focused transient immune suppression protocol for efficient AAV readministration to the liver","author":"Rana","year":"2024","journal-title":"Mol Ther Meth Clin Develop"},{"key":"10.1016\/j.blre.2025.101356_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3505","article-title":"Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice","volume":"25","author":"Baatartsogt","year":"2023","journal-title":"J Gene Med"},{"key":"10.1016\/j.blre.2025.101356_bb0240","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jtha.2025.02.042","article-title":"Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance","volume":"23","author":"Konkle","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101356_bb0245","series-title":"Analysis of Elevated Alanine Transaminase in HOPE-B, a Phase 3 recombinantadeno-associated viral 5 Gene Therapy Trial in People with haemophilia B","author":"Astermark","year":"2023"},{"key":"10.1016\/j.blre.2025.101356_bb0250","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41575-022-00729-0","article-title":"Gene therapy for liver diseases \u2014 progress and challenges","volume":"20","author":"Zabaleta","year":"2023","journal-title":"Nature reviews. Gastroenterol Hepatol"},{"key":"10.1016\/j.blre.2025.101356_bb0260","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/bloodadvances.2024015184","article-title":"Gene therapy for hemophilia B: results from the phase 1\/2 101HEMB01\/02 studies","volume":"9","author":"Pipe","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101356_bb0265","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101356_bb0270","series-title":"Efficacy and Safety of FACTOR IX Padua Gene Transfer via BBM-H901 among Chinese patients with Haemophilia B: A Multicentre, Single-arm, Phase 1\/2 and 3 Study and Long-term Follow-up of a Phase 1 Pilot Study","author":"Zhang","year":"2025"},{"key":"10.1016\/j.blre.2025.101356_bb0275","series-title":"(etranacogene dezaparvovec-drlb) suspension Prescribing Information","author":"HEMGENIX","year":"2025"},{"key":"10.1016\/j.blre.2025.101356_bb0280","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/JBM.S371438","article-title":"Gene therapy and Hemophilia: where do we go from Here?","volume":"13","author":"Bolous","year":"2022","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2025.101356_bb0285","first-page":"1354","article-title":"Long-term toxicity of immunosuppressive therapy. Transplantation of the","author":"Ruiz","year":"2015","journal-title":"Liver"},{"key":"10.1016\/j.blre.2025.101356_bb0290","doi-asserted-by":"crossref","first-page":"2340283","DOI":"10.2217\/frd-2023-0027","article-title":"How long do the effects of gene therapy based on adeno-associated virus last? A plain language summary","volume":"4","author":"Moroz","year":"2024","journal-title":"Future Rare Dis"},{"key":"10.1016\/j.blre.2025.101356_bb0295","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2024-204715","article-title":"Efficacy and safety of an engineered, liver-tropic adeno-associated virus vector expressing factor IX Padua administered with prophylactic glucocorticoids in patients with Hemophilia B: a multi-Center, single-arm, phase 3 trial","volume":"144","author":"Xue","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101356_bb0300","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101356_bb0305","first-page":"134","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","author":"Salabarria","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101356_bb0315","article-title":"A versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101356_bb0320","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2023.018","article-title":"Complement activation by adeno-associated virus-neutralizing antibody complexes","volume":"34","author":"West","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0325","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1091581817740873","article-title":"Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases","volume":"36","author":"Lansita","year":"2017","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.blre.2025.101356_bb0330","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ymthe.2004.10.020","article-title":"Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo","volume":"11","author":"Jennings","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0335","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/mt.2010.170","article-title":"Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application","volume":"18","author":"Monahan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101356_bb0340","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101356_bb0345","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1038\/s41598-018-21742-x","article-title":"Oligonucleotide conjugated multi-functional adeno-associated viruses","volume":"8","author":"Katrekar","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2025.101356_bb0350","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177231","article-title":"Evaluating precision medicine approaches for gene therapy in patient-specific cellular models of Bietti crystalline dystrophy","volume":"9","author":"Li","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2025.101356_bb0355","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cytogfr.2024.09.003","article-title":"Adeno-associated virus therapies: pioneering solutions for human genetic diseases","volume":"80","author":"Liu","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.blre.2025.101356_bb0360","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101356_bb0365","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.blre.2025.101356_bb0370","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101356_bb0375","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.79.17.11434-11442.2005","article-title":"Large-scale analysis of adeno-associated virus vector integration sites in Normal human cells","volume":"79","author":"Miller","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2025.101356_bb0380","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","volume":"42","author":"Greig","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.blre.2025.101356_bb0385","series-title":"Kinetic Modeling of Transaminase Values Distinguishes Active Liver Inflammation from Resolution Independent of Absolute Enzyme Levels","author":"Sherman","year":"2022"},{"key":"10.1016\/j.blre.2025.101356_bb0390","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CBF.S27901","article-title":"Current and emerging biomarkers of hepatotoxicity","author":"Schnackenberg","year":"2012","journal-title":"CBF"},{"key":"10.1016\/j.blre.2025.101356_bb0395","first-page":"410","article-title":"Chinese guidance for clinical application of adeno-associated virus vector-based gene therapy for hemophilia B (2025)","volume":"46","author":"Zhang","year":"2025","journal-title":"Chin J Hematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:21:09Z","timestamp":1773915669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":77,"alternative-id":["S0268960X25001018"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101356","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda (China) International Trading Co. Ltd. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101356"}}